Clinical Trials Logo

Hernia, Ventral clinical trials

View clinical trials related to Hernia, Ventral.

Filter by:

NCT ID: NCT04787874 Recruiting - Ventral Hernia Clinical Trials

Effect of Prehabilitation on Surgical Outcomes of Abdominally-based Plastic Surgery Procedures

Start date: June 21, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether a program to optimize patient physical fitness and nutrition ("prehabilitation") prior to and after plastic surgery involving the abdomen improves surgical outcomes. The investigators hope to determine how a multimodal peri-operative prehabilitation program can be most effective in engaging and motivating patients to physically and mentally get ready for an abdominally-based plastic surgery operation. The overall goal is to determine if this program will improve post-operative recovery after abdominally-based plastic surgery. The importance of this new knowledge is better understanding of ways that plastic surgeons can improve outcomes, engagement, and experience of patients undergoing abdominally-based plastic surgery operations. This would translate to increased healthcare value and better long-term outcomes.

NCT ID: NCT04785638 Completed - Pain, Postoperative Clinical Trials

An Open-label Safety and Pharmacokinetic Study of INL-001 in Adults Following Various Open Soft-Tissue Surgeries

Start date: April 14, 2021
Phase: Phase 3
Study type: Interventional

This is a multicenter, Phase 3, open-label, safety, tolerability, and characterization of pharmacokinetics study of the INL 001 (bupivacaine HCl) implant, at 300 mg, in patients following various soft-tissue surgeries: open ventral hernia repair, abdominoplasty, open abdominal hysterectomy, laparoscopic-assisted colectomy, and reduction mammoplasty.

NCT ID: NCT04779918 Recruiting - Hernia, Inguinal Clinical Trials

Ventral or Inguinal Hernia, Robotically Repaired With OviTex Mesh

BRAVOII
Start date: April 14, 2021
Phase: N/A
Study type: Interventional

This study is designed to evaluate the post-operative complications and hernia recurrence following the use of OviTex in subjects with ventral or inguinal hernias. Up to 160 subjects will participate in the study from up to 20 investigator sites.

NCT ID: NCT04774328 Completed - Postsurgical Pain Clinical Trials

Preliminary Study of CA-008 (Vocacapsaicin) in Patients Undergoing Ventral Hernia Repair

Start date: September 9, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

A Three-Part, Phase 1/2, Randomized, Double-blind, Placebo-Controlled, Adaptive Safety, Pharmacokinetics, and Preliminary Efficacy Study of CA-008 (Vocacapsaicin) in Patients Undergoing Ventral Hernia Repair

NCT ID: NCT04726644 Completed - Clinical trials for Ventral Hernias in Cirrhotic Patients

Evaluation of Surgical Techniques in Cirrhotic Patients With Ventral Hernias

Start date: January 1, 2017
Phase:
Study type: Observational [Patient Registry]

ventral hernias are defects of the anterior abdominal wall, which can be congenital or acquired including epigastric, umbilical and incisional hernia. Umbilical hernias represent a common surgical problem in cirrhotic patient with ascites with 20% incidence. This work was deigned to assess outcome of different techniques of closure of ventral hernias in cirrhotic patients.

NCT ID: NCT04718168 Recruiting - Incisional Hernia Clinical Trials

GORE® ENFORM Biomaterial Product Study

ENF 18-06
Start date: May 17, 2021
Phase: N/A
Study type: Interventional

A prospective, retrospective, non-randomized, multicenter study with two independent hernia study cohorts (Ventral / Incisional Hernia Repair and Diaphragmatic / Hiatal Hernia Repair). The primary objective of this study is to collect GORE® ENFORM Biomaterial product commercial-use data on device functional performance.

NCT ID: NCT04683367 Completed - Laparoscopy Clinical Trials

Follow-up of Symptomless Inguinal and Ventral Hernias

hernia
Start date: January 1, 2003
Phase: N/A
Study type: Interventional

The orifices of all inguinal and ventral (including Spigelian) hernias were carefully recorded at the beginning of laparoscopy (n=201) of other reason (cholecystectomy, fundoplication) in 2003-5. The patients with occult hernias (n=43) were followed-up 15 years to find out what percentage of hernias would become symptomatic.

NCT ID: NCT04624100 Not yet recruiting - Clinical trials for Ventral Incisional Hernia

Quality Control of Ventral Hernia Surgery by Prospective Registration

Start date: July 1, 2024
Phase:
Study type: Observational [Patient Registry]

Quality Control of ventral hernia surgery in 21 Belgian hospitals by prospective registration in close collaboration with the Danish Hernia Database.

NCT ID: NCT04597840 Recruiting - Clinical trials for Ventral Hernia Repair

Biosynthetic Absorbable Mesh vs Standard of Repair for the Surgical Treatment of Infected Incisional Hernia

COMpACT-BIO
Start date: May 25, 2021
Phase: N/A
Study type: Interventional

Incisional hernia is one of the most common complications of abdominal surgery and carries a significant burden for both patients and the economic health service. However, no consensus for the surgical treatment of incisional hernia in contaminated field is currently available. The purpose of the COMpACT-BIO study is to investigate the clinical and economic benefit of the use of biosynthetic mesh in contaminated incisional hernia repair.

NCT ID: NCT04580524 Withdrawn - Ventral Hernia Clinical Trials

Phasix Mesh Use in Complex Open Ventral Hernias Study

Start date: April 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to compare clinical and patient centered outcomes of biosynthetic poly-4-hydroybutyrate meshes versus current care (synthetic polypropylene mesh or suture) for complex ventral hernia repair. The primary outcome for this study will be patients who are major complication free at 2 years postoperative. This will be a composite of hernia recurrence, reoperation, chronic wound complication, or death. Secondary outcomes include: surgical site occurences such as surgical site infection, seroma, hematoma and skin dehiscence within 90 days postoperative, emergency room visits withing 90 days postoperative, days in hospital up to 90 days postoperative, abdominal pain, and change in patient centered outcomes measured through the modified activities assessment scale (mAAS).